Payoneer Global Inc vs uniQure N.V. Ordinary Shares — how do they compare? Payoneer Global Inc trades at $7.13 (market cap $2.42B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: Payoneer Global Inc is the larger of the two by market cap, and Payoneer Global Inc is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Payoneer Global Inc for 62 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| PAYO | QURE | |
|---|---|---|
Market Cap | $2.42B | $1.48B |
Volume | 1,032,721 | 2,488,780 |
Sector | Technology | Health |
52-Week High | $7.18 | $70.59 |
52-Week Low | $4.27 | $9.03 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $2.16B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.14, up 0.28% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. Fundamentally, the company reported Q2 2026 earnings of $0.02 per share, missing estimates, but revenue grew 10% excluding interest. Recent news highlights the renewal of its partnership with Etsy through 2029 and an agreement to be acquired by Nuvei, announced on June 15, 2026.
The outlook is shaped by the pending acquisition, which offers a potential exit for shareholders, but execution risks and recent earnings misses pose concerns. Analyst sentiment is positive with a 60% buy rating, yet investors should weigh acquisition certainty against operational performance volatility and competitive pressures in the fintech sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →